Bristol Myers Squibb (BMY) on Thursday said its Phase 2 study of deucravacitinib dubbed LATTICE-UC in moderate to severe ulcerative colitis (UC) did not meet the primary efficacy endpoint.
The study, whose primary end point was clinical remission at Week 12, did not meet secondary endpoints too, the company said. "While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn's disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases," said Samit Hirawat, chief medical officer, Bristol Myers Squibb.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.